Researchers Reveal Potential Advancement in Postponing Alzheimer's Disease
The latest results from a study led by scientists at the Washington University School of Medicine have provided early evidence that an experimental anti-amyloid drug called gantenerumab could help delay symptoms in people genetically fated to develop Alzheimer's at a young age.
Gantenerumab targets beta amyloid, one of two proteins thought to play a critical role in causing Alzheimer's. It is one of many similar drugs developed for Alzheimer's, but its development was previously halted by pharmaceutical company Roche due to failed Phase III trials.
The study included a total of 73 patients who were genetically fated to develop Alzheimer's. The trial ended earlier than expected for many patients due to Roche's abandonment of the drug. However, some patients continued to receive the drug as part of an extension study, initiated by the researchers.
In a subset of patients treated the longest, the drug appeared to reduce their risk of developing symptoms by 50%. This suggests that gantenerumab may have the potential to slow down the progression of Alzheimer's in genetically predisposed individuals.
However, it's important to note that the reduction in the risk of cognitive decline in the overall group of symptomless people wasn't statistically significant. Additionally, about a third of the patients developed amyloid-related imaging abnormalities (ARIAs), a known side-effect of these drugs. Two patients experienced severe ARIAs, which prompted the researchers to stop treatment, after which they recovered.
The researchers behind the gantenerumab study decided to openly provide the drug to its patients as part of an extension study. This decision is significant, as it allows for further investigation into the drug's effects and potential benefits.
Despite the promising findings, it's crucial to approach these results with caution. The study is still ongoing, and more research is needed to confirm the drug's efficacy and safety.
There are ongoing prevention trials for both early-onset and classic Alzheimer's, including several being run by WashU through its Dominantly Inherited Alzheimer Network-Trials Unit. These trials will provide valuable insights into the potential of drugs like gantenerumab in preventing or delaying the onset of Alzheimer's.
In the past, many anti-amyloid drugs have shown promise early on, only to fail in larger trials that tested them for people already experiencing Alzheimer's symptoms. The gantenerumab study's focus on asymptomatic patients represents a shift in strategy, offering hope for future Alzheimer's treatments.
The latest results from the gantenerumab study were published in The Lancet Neurology on Wednesday, shedding light on a potential new approach in the fight against Alzheimer's disease.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
